| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:49 UTC |
|---|
| HMDB ID | HMDB0015017 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Emtricitabine |
|---|
| Description | Emtricitabine is only found in individuals that have used or taken this drug. It is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. Emtricitabine works by inhibiting reverse transcriptase (RT), an enzyme that allows the virus to multiply by copying HIV RNA into new viral DNA. The drug competes with the reverse transcriptase's natural substrate deoxycytidine 5'-triphosphate and also becomes incorporated into viral DNA. This is a result of emtricitabine being a synthetic nucleoside analogue of cytidine. It is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate which competes with the natural substrate deoxycytidine 5'-triphosphate and becomes incorporated into nascent viral DNA, resulting in early chain termination. By inhibiting HIV-1 reverse transcriptase, emtricitabine can help to lower the amount of HIV (viral load) in a patient's body and can indirectly increase the number of immune system cells (T cells or CD4+ T-cells). Both of these changes are associated with healthier immune systems and a decreased likelihood of serious illness. Emtricitabine is always used in conjunction with other HIV medicine to treat people with HIV infection. |
|---|
| Structure | NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1 InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine | ChEBI | | (-)-2'-Deoxy-5-fluoro-3'-thiacytidine | ChEBI | | (-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine | ChEBI | | (-)-cis-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one | ChEBI | | (-)-FTC | ChEBI | | (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone | ChEBI | | 4-Amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one | ChEBI | | 4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one | ChEBI | | 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine | ChEBI | | Emtriva | Kegg | | ABBR FTC | Kegg | | (-)-b-2',3'-Dideoxy-5-fluoro-3'-thiacytidine | Generator | | (-)-Β-2',3'-dideoxy-5-fluoro-3'-thiacytidine | Generator | | (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine | HMDB | | (-)-Emtricitabine | HMDB | | Coviracil | HMDB | | Emtricitabine | HMDB | | Beta L 2',3' Dideoxy 5 fluoro 3' thiacytidine | MeSH | | beta-L-2',3'-Dideoxy-5-fluoro-3'-thiacytidine | MeSH |
|
|---|
| Chemical Formula | C8H10FN3O3S |
|---|
| Average Molecular Weight | 247.247 |
|---|
| Monoisotopic Molecular Weight | 247.042690096 |
|---|
| IUPAC Name | 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one |
|---|
| Traditional Name | emtricitabine |
|---|
| CAS Registry Number | 143491-57-0 |
|---|
| SMILES | NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1 |
|---|
| InChI Identifier | InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1 |
|---|
| InChI Key | XQSPYNMVSIKCOC-NTSWFWBYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 3'-thia pyrimidine nucleosides. These are nucleoside analogues with a structure that consists of a pyrimidine base, which is N-substituted at the 1-position with a 3'-thia derivative (1,3-oxazolidine) of the ribose moiety that is characteristic of nucleosides. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Nucleosides, nucleotides, and analogues |
|---|
| Class | Nucleoside and nucleotide analogues |
|---|
| Sub Class | 3'-thia pyrimidine nucleosides |
|---|
| Direct Parent | 3'-thia pyrimidine nucleosides |
|---|
| Alternative Parents | |
|---|
| Substituents | - 3'-thia pyrimidine nucleoside
- Aminopyrimidine
- Halopyrimidine
- Pyrimidone
- Aryl fluoride
- Aryl halide
- Hydropyrimidine
- Pyrimidine
- Imidolactam
- Heteroaromatic compound
- Monothioacetal
- Oxathiolane
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Amine
- Organooxygen compound
- Organonitrogen compound
- Organofluoride
- Organohalogen compound
- Alcohol
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Primary alcohol
- Primary amine
- Organic nitrogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 136 - 140 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 2 g/L | Not Available | | LogP | -1.4 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.26 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.9118 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.37 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 29.9 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 877.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 275.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 95.3 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 170.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 70.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 302.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 326.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 115.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 729.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 275.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 807.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 228.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 203.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 380.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 251.9 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 114.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Emtricitabine,1TMS,isomer #1 | C[Si](C)(C)OC[C@@H]1O[C@H](N2C=C(F)C(N)=NC2=O)CS1 | 2286.5 | Semi standard non polar | 33892256 | | Emtricitabine,1TMS,isomer #2 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F | 2310.0 | Semi standard non polar | 33892256 | | Emtricitabine,2TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2CS[C@H](CO[Si](C)(C)C)O2)C=C1F | 2378.8 | Semi standard non polar | 33892256 | | Emtricitabine,2TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2CS[C@H](CO[Si](C)(C)C)O2)C=C1F | 2048.1 | Standard non polar | 33892256 | | Emtricitabine,2TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2CS[C@H](CO[Si](C)(C)C)O2)C=C1F | 3158.8 | Standard polar | 33892256 | | Emtricitabine,2TMS,isomer #2 | C[Si](C)(C)N(C1=NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F)[Si](C)(C)C | 2336.6 | Semi standard non polar | 33892256 | | Emtricitabine,2TMS,isomer #2 | C[Si](C)(C)N(C1=NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F)[Si](C)(C)C | 2239.2 | Standard non polar | 33892256 | | Emtricitabine,2TMS,isomer #2 | C[Si](C)(C)N(C1=NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F)[Si](C)(C)C | 3225.2 | Standard polar | 33892256 | | Emtricitabine,3TMS,isomer #1 | C[Si](C)(C)OC[C@@H]1O[C@H](N2C=C(F)C(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)CS1 | 2382.5 | Semi standard non polar | 33892256 | | Emtricitabine,3TMS,isomer #1 | C[Si](C)(C)OC[C@@H]1O[C@H](N2C=C(F)C(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)CS1 | 2318.6 | Standard non polar | 33892256 | | Emtricitabine,3TMS,isomer #1 | C[Si](C)(C)OC[C@@H]1O[C@H](N2C=C(F)C(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)CS1 | 2803.2 | Standard polar | 33892256 | | Emtricitabine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@@H]1O[C@H](N2C=C(F)C(N)=NC2=O)CS1 | 2536.5 | Semi standard non polar | 33892256 | | Emtricitabine,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F | 2553.1 | Semi standard non polar | 33892256 | | Emtricitabine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2CS[C@H](CO[Si](C)(C)C(C)(C)C)O2)C=C1F | 2816.7 | Semi standard non polar | 33892256 | | Emtricitabine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2CS[C@H](CO[Si](C)(C)C(C)(C)C)O2)C=C1F | 2428.4 | Standard non polar | 33892256 | | Emtricitabine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2CS[C@H](CO[Si](C)(C)C(C)(C)C)O2)C=C1F | 3218.1 | Standard polar | 33892256 | | Emtricitabine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C1=NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F)[Si](C)(C)C(C)(C)C | 2765.6 | Semi standard non polar | 33892256 | | Emtricitabine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C1=NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F)[Si](C)(C)C(C)(C)C | 2755.4 | Standard non polar | 33892256 | | Emtricitabine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C1=NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F)[Si](C)(C)C(C)(C)C | 3195.9 | Standard polar | 33892256 | | Emtricitabine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@@H]1O[C@H](N2C=C(F)C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)CS1 | 3003.8 | Semi standard non polar | 33892256 | | Emtricitabine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@@H]1O[C@H](N2C=C(F)C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)CS1 | 3009.9 | Standard non polar | 33892256 | | Emtricitabine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@@H]1O[C@H](N2C=C(F)C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)CS1 | 3023.1 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Emtricitabine GC-MS (Non-derivatized) - 70eV, Positive | splash10-005c-9840000000-916eed674e8dde443d6e | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Emtricitabine GC-MS (1 TMS) - 70eV, Positive | splash10-0fep-8292000000-b2dcf9a13b9a869927cc | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Emtricitabine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Emtricitabine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , negative-QTOF | splash10-0udi-0900000000-70cf3fd58a0517da4a55 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , negative-QTOF | splash10-0udi-0900000000-94b3e0720e27e6745a1f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , negative-QTOF | splash10-0udi-0900000000-8dbfc14b46cc1f58e910 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , negative-QTOF | splash10-0udi-0900000000-2dad282fe8707980881d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , negative-QTOF | splash10-0udi-1900000000-efef9ecafd739446f7ae | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , negative-QTOF | splash10-0udi-2900000000-349c2005cbcd9008b160 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , positive-QTOF | splash10-001i-0900000000-6dae6d5531a8a2f408cd | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , positive-QTOF | splash10-001i-0900000000-b8b0b2a41b04924a3ae6 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , positive-QTOF | splash10-001i-0900000000-b0b20b1959137a52d9c7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , positive-QTOF | splash10-001i-0900000000-bd2c9f863694963a9078 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , positive-QTOF | splash10-001i-1900000000-9903921aee7742b373e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine LC-ESI-QFT , positive-QTOF | splash10-001i-1900000000-8857a02a53df79efbd5c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine 30V, Positive-QTOF | splash10-001i-0900000000-961f6f9132af62bc5e1e | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine 15V, Positive-QTOF | splash10-001i-0900000000-09ba1f683ca6a306fa48 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine 45V, Positive-QTOF | splash10-001i-0900000000-85e4574e24a912428e0d | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine 75V, Negative-QTOF | splash10-0udi-1900000000-98f516d8a1dfac9bd187 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine 90V, Negative-QTOF | splash10-0udi-2900000000-d38aba7b54ffd5599634 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine 60V, Positive-QTOF | splash10-001i-0900000000-77bf43e48b391e0cc9e6 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Emtricitabine 30V, Negative-QTOF | splash10-0udi-0900000000-f3f824943162b24c1e4f | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Emtricitabine 10V, Positive-QTOF | splash10-001i-0920000000-810d7a7def89643865a6 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Emtricitabine 20V, Positive-QTOF | splash10-001i-1900000000-009baab415006b7bc307 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Emtricitabine 40V, Positive-QTOF | splash10-001i-6900000000-4ee98d10e3447b6c66ac | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Emtricitabine 10V, Negative-QTOF | splash10-002b-2390000000-77ee7291923983e61f8b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Emtricitabine 20V, Negative-QTOF | splash10-0ukl-1910000000-fa4bf50b1d66f4072746 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Emtricitabine 40V, Negative-QTOF | splash10-00di-9100000000-634ee8be27db1e259199 | 2016-08-03 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum |
|
|---|